Authors

Main Content

Top Content

Directory of Authors from the Journal and their last article.

Thomas HuebnerView Articles

Volume 19, Number 1Review Articles

Prostate Biopsy Characteristics: A Comparison Between Pre- and Post-United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012

Cancer Screening Assessment

Navin ShahVladimir IoffeThomas HuebnerRichard Hum

This article compares prostate cancer (PCa) characteristics diagnosed by prostate biopsy in the years before and after the 2012 United States Preventative Service Task Force (USPSTF) recommendations against PCa screening. We completed a retrospective comparative analysis of 402 sequential PCa biopsy-diagnosed patients in 2010 to 2012 (3 years) with 269 PCa patients diagnosed in 2015 to 2016 (18 months). Data were collected on patient age, total number of biopsies performed, prostate-specific antigen level, Gleason sum score, and digital rectal examination results. The data were analyzed to determine whether the 2012 USPSTF screening recommendations affected PCa characteristics. [ Rev Urol. 2017;19(1):25-31 doi: 10.3909/riu0745] © 2017 MedReviews®, LLC

Prostate cancerCancer screening

Thomas J GuzzoView Articles

Volume 12, Number 4Case Review

Neuroendocrine Tumor of the Bladder

Alan J WeinShailen S SehgalZhanyong BingThomas J Guzzo

Small cell carcinoma (SCC) of the bladder is a rare and aggressive tumor associated with a poor prognosis. It often presents at a later stage than urothelial carcinoma of the bladder, and comprises less than 1% of bladder malignancies. A number of treatment algorithms have been used to treat bladder SCC, including cystectomy, partial cystectomy, radiotherapy, chemoradiotherapy, chemotherapy alone, and neoadjuvant/adjuvant chemotherapy. Presented is a case of SCC of the bladder, and the epidemiology, prognosis, and current treatment algorithms for patients with bladder SCC are reviewed.[Rev Urol. 2010;12(4):e197-e201 doi: 10.3909/riu0492]©2010 MedReviews®, LLC

Bladder cancerNeuroendocrine tumorsSmall cell carcinoma

Thomas J MuellerView Articles

Volume 19, Number 2Review Articles

Utilization of Individualized Prostate Cancer and Genomic Biomarkers for the Practicing Urologist

Management Update

Gregory C McMahonGordon A BrownThomas J Mueller

Prostate cancer encompasses a complex heterogeneous disease spectrum. Physicians and patients are faced with the ambiguity of who should be screened, biopsied, rebiopsied, treated, or provided with adjuvant therapy. Personalized outcomes and treatments are especially important given the varied nature of the disease, plethora of treatment options, risks of morbidity, and quality of life. Today’s practicing urologist has a multitude of tests from which to choose, creating the difficult task of appropriate use. This review focuses on two blood-, one urine-, and five genomic-based tests, which, when used in the appropriate clinical setting, can facilitate the patient-physician decision-making process. [Rev Urol. 2017;19(2):97–105 doi:10.3909/riu0730] © 2017 MedReviews®, LLC

Prostate cancerGenomic testsPersonalized medicine

Thomas J PolascikView Articles
Thomas M SchroederView Articles

Volume 19, Number 3Case Review

High Postprostatectomy Prostate-specific Antigen Level Prior to Salvage Radiation Therapy Is Not Always a Bad Sign

John T RathbunThomas M SchroederSteven C Eberhardt

Although radical prostatectomy is a popular treatment modality for clinically localized prostate cancer, 10-year biochemical recurrence can reach 28%. Before salvage radiation therapy (SRT), prostate-specific antigen (PSA) values alone should be used cautiously in predicting SRT eligibility. A long, slow PSA rise may suggest locally confined disease still amenable to SRT; corresponding imaging to identify potential gross recurrence is useful. Patients with local disease may safely benefit from higher doses of radiation. [Rev Urol. 2017;19(3):190–194 doi: 10.3909/riu0754] © 2017 MedReviews®, LLC

Prostate-specific antigenRadical prostatectomySalvage radiation therapy

Thomas M WheelerView Articles
Thomas MageeView Articles
Thomas SchwaabView Articles

Volume 12, Number 4Case Review

Spontaneous Rupture of a Renal Artery Aneurysm Presenting as Gross Hematuria

Shawn EL WasonThomas Schwaab

Renal artery aneurysms (RAAs) are localized dilations of the renal artery and/or its branches. They are being found with increasing frequency as a result of unrelated abdominal imaging or on workup for hypertension. They are rarely symptomatic; however, they can be a cause of life-threatening hematuria. Discussed is the case of a previously healthy 46-year-old man presenting with flank pain and gross hematuria. It is imperative for the practicing urologist to be aware of the appropriate evaluation and management of RAAs.[Rev Urol. 2010;12(4):e193-e196 doi: 10.3909/riu0489]© 2010 MedReviews®, LLC

Renal artery aneurysmAbdominal aortographyGross hematuria

Tiffany A PerkinsView Articles

Volume 16, Number 2Case Review

Solitary Candida albicans Infection Causing Fournier Gangrene and Review of Fungal Etiologies

Tiffany A PerkinsJared M BieniekJoel M Sumfest

Polymicrobial bacterial infections are commonly found in cases of Fournier gangrene (FG), although fungal growth may occur occasionally. Solitary fungal organisms causing FG have rarely been reported. The authors describe a case of an elderly man with a history of diabetes who presented with a necrotizing scrotal and perineal soft tissue infection. He underwent emergent surgical debridement with findings of diffuse urethral stricture disease and urinary extravasation requiring suprapubic tube placement. Candida albicans was found to be the single causative organism on culture, and the patient recovered well following antifungal treatment. Fungal infections should be considered as rare causes of necrotizing fasciitis and antifungal treatment considered in at-risk immunodeficient individuals. [Rev Urol. 2014;16(2):95-98 doi: 10.3909/riu0595] © 2014 MedReviews®, LLC

Fournier gangreneFournier’s Gangrene Severity IndexCandida albicans

Tim LaneView Articles

Volume 16, Number 1Review Articles

The Physiologic and Anesthetic Considerations in Elderly Patients Undergoing Robotic Renal Surgery

Management Review

Nikhil VasdevTim LaneDamian HanburyAnna Sau Kuk PoonGowrie MohanGregory BousteadJames M Adshead

A number of patients are diagnosed with renal malignancies incidentally worldwide. Once a diagnosis of a renal malignancy is established, after a careful evaluation, patients can be offered a robotic nephrectomy or partial nephrectomy. We present a review of the physiologic and anesthetic considerations in elderly patients who are being considered for robotic renal surgery. [Rev Urol. 2014;16(1):1-9 doi: 10.3909/riu0591] © 2014 MedReviews®, LLC

Robotic partial nephrectomyRobotic radical nephrectomyPhysiologic considerationsAnesthetic considerations

Timothy B BooneView Articles
Timothy D LyonView Articles

Volume 19, Number 2Review Articles

The Use of Intraoperative Cell Salvage in Urologic Oncology

Surgical Update

Andres F CorreaMatthew C FerroniTimothy D LyonBenjamin J DaviesMichael C Ost

Intraoperative cell salvage (IOCS) has been used in urologic surgery for over 20 years to manage intraoperative blood loss and effectively minimize the need for allogenic blood transfusion. Concerns about viability of transfused erythrocytes and potential dissemination of malignant cells have been addressed in the urologic literature. We present a comprehensive review of the use of IOCS in urologic oncologic surgery. IOCS has been shown to preserve the integrity of erythrocytes during processing and effectively provides cell filtration to mitigate the risk of tumor dissemination. Its use is associated with reduction in the overall need for allogenic blood transfusion, which clinically reduces the risk of hypersensitivity reactions and disease transmission, and may have important implications on overall oncologic outcomes. In the context of a variety of urologic malignancies, including prostate, urothelial, and renal cancer, the use of IOCS appears to be safe, without risk of tumor spread leading to metastatic disease or differences in cancer-specific and overall survival. IOCS has been shown to be an effective intraoperative blood management strategy that appears safe for use in urologic oncology surgery. The ability to reduce the need for additional allogenic blood transfusion may have significant impact on immune-mediated oncologic outcomes. [Rev Urol. 2017;19(2):89–96 doi: 10.3909/riu0721] © 2017 MedReviews®, LLC

Urologic oncologyCell salvagetransfusion

Timothy J WiltView Articles
Timothy W StarkView Articles

Volume 18, Number 1Case Review

Management of Vesicoureteral Reflux by Endoscopic Injection of Dextranomer/Hyaluronic Acid in Adults

Timothy W StarkJohn M LacyDavid M Preston

A 74-year-old man presented for evaluation after discovery of a left bladder-wall tumor. He underwent transurethral resection of bladder tumor (TURBT) operation for treatment of low-grade, Ta urothelial cancer of the bladder. The patient developed recurrent disease and returned to the operating room for repeat TURBT, circumcision, and administration of intravesical mitomycin C. The patient developed balanitis xerotica obliterans 4 years post-circumcision, requiring self-dilation with a catheter. He subsequently developed 3 consecutive episodes of left-sided pyelonephritis. Further investigation with voiding cystourethrogram (VCUG) revealed Grade 3, left-sided vesicoureteral reflux (VUR). Due to existing comorbidities, the patient elected treatment with endoscopic dextranomer/hyaluronic acid injection. A post-operative VCUG demonstrated complete resolution of left-sided VUR. This patient has remained symptom free for 8 months post-injection, with no episodes of pyelonephritis. [Rev Urol. 2016;18(1):46-50 doi: 10.3909/riu0689] © 2016 MedReviews®, LLC

Vesicoureteral refluxPyelonephritisDextranomer/hyaluronic acid

Tin C NgoView Articles

Volume 9, Number 1Review Articles

Uric Acid Nephrolithiasis: Recent Progress and Future Directions

Management Update

Dean G AssimosTin C Ngo

The prevalence of urolithiasis has been increasing for the past few decades in industrialized nations. Uric acid calculi account for a significant percentage of urinary stones. Certain risk factors may be involved in the pathogenesis of uric acid nephrolithiasis, including hyperuricosuria, low urinary volume, and persistently low urinary pH. Patients with medical conditions that promote profound hyperuricosuria are at high risk of developing uric acid calculi. These conditions include chronic diarrheal states; myeloproliferative disorders; insulin resistance, including diabetes mellitus; and monogenic metabolic disorders, such as Lesch-Nyhan syndrome. Computed tomography can provide a definitive diagnosis. Except in cases in which there is severe obstruction, progressive azotemia, serious infection, or unremitting pain, the initial treatment of patients with uric acid nephrolithiasis should be medical dissolution therapy because this approach is successful in the majority of cases. A thorough review of the epidemiology and pathophysiology of uric acid nephrolithiasis is crucial for the diagnosis, treatment, and prevention of stones in patients with this condition. [Rev Urol. 2007;9(1):17-27]

UrolithiasisUric acid nephrolithiasisHyperuricosuriaGout

Tobias KlatteView Articles

Volume 8, Number 3Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Danil V MakarovEllen ShapiroAlan W PartinMichael B ChancellorVictor W NittiJ Curtis NickelJacob RajferClaus G RoehrbornMichael K BrawerArie S BelldegrunJohn P SteinJohn P MulhallTobias KlatteMichael E AldridgeLi-Ming SuShachi Tyagi

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancerInfertilityBenign prostatic hyperplasiaBladder cancerKidney cancerLower urinary tract symptomsBladder exstrophyOveractive bladderInterstitial cystitisStress urinary incontinencePeyronie’s diseaseSpina bifidaNeurogenic bladderErectile dysfunctionChronic pelvic pain syndromeChronic prostatitisTumor markersAndrogen replacement therapyEjaculatory dysfunctionAnorectal malformationsRenal stonesRobotic-assisted radical prostatectomy

Toby F HandlerView Articles
Tom F LueView Articles
Tomasz M BeerView Articles
Tommaso BrancatoView Articles

Volume 16, Number 1Review Articles

Nephron-sparing Management of Upper Tract Urothelial Carcinoma

Management Review

Tommaso BrancatoFrancesca Suriano

Upper tract urothelial carcinoma (UTUC) is a relatively rare tumor, but is characterized by high rates of recurrence, morbidity, and mortality. Choice of treatment modality is generally influenced by lesion size, grade, and focality. Radical nephroureterectomy with bladder cuff excision is the gold-standard management of UTUC, although an organ-sparing approach may be beneficial in selected patients. Conservative endoscopic management of UTUC in appropriate patients has a favorable impact on quality of life and health care costs when compared with patients who progress to dialysis-dependent renal failure. Careful ureteroscopic surveillance following endoscopic management of UTUC is essential. [Rev Urol. 2014;16(1):21-28 doi: 10.3909/riu0592] © 2014 MedReviews®, LLC

Upper tract urothelial carcinomaTumor gradeNephron-sparing endoscopic treatmentTopical adjuvant chemo-immunotherapyOncologic outcomes